Bibliography
- Critical Path Opportunities Report. US Department of Health and Human Services, Food and Drug Administration, March 2006
- Hawkridge AM, Muddiman DC. Mass spectrometry-based biomarker discovery: toward a global proteome index of individuality. Ann Rev Anal Chem 2009; doi:10.1146/annurev.anchem.1.031207.112942
- Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95
- Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007;6:287-93
- Lanoix J, Paramithiotis E. Secretory vesicle analysis for discovery of low abundance plasma proteins. Expert Opin Med Diagn 2008;2:1-11
- Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomarker Insights 2006;1:1-48
- Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007;27:15-26
- Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotech 2006;24:971-83
- McGuire JN, Overgaard J, Pociot F. Mass spectrometry is only one piece of the puzzle in clinical proteomics. Brief Funct Genomic Proteomic 2008;7:74-83
- Marrer E, Dieterie F. Promises of biomarkers in drug development – a reality check. Chem Biol Drug Des 2007;69:381-94
- Vitzthum F, Behrens F, Anderson NL, Proteomics: from basic research to diagnostic application. A review of requirements and needs. J Proteome Res 2005;4:1086-97
- Lee JW, Figeys D, Vasilescu J. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. Adv Cancer Res 2007;96:269-98
- Alaiya A, Al-Mohanna M, Linder S. Clinical cancer proteomics: promises and pitfalls. J Proteome Res 2005;4:1213-22
- Sawyers CL. The cancer biomarker problem. Nature 2008;452:548-52
- Simpson RJ, Bernhard OK, Greening DW, Proteomics-driven cancer biomarker discovery: looking to the future. Curr Opin Chem Biol 2008;12:72-7
- Pusztai L, Mazouni C, Anderson K, Molecular classification of breast cancer: limitations and potential. Oncologist 2006;11:868-77
- Glassman RH, Ratain MJ. Biomarkers in early cancer development: limited utility. Clin Pharmacol Ther 2009;85:134-5
- Shorr AF, Nelson DR, Wyncoll DLA, Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). Crit Care 2008;12:R45
- Vangerow B, Shorr AF, Wyncoll D, The protein C pathway: implications for the design of the RESPOND study. Crit Care 2007;11:S4
- Podwojski K, Fritsch A, Chamrad DC, Retention time alignment algorithms for LC/MS data must consider nonlinear shifts. Bioinformatics 2009;25:758-64
- Pan S, Aebersold R, Chen R, Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res 2008;8:787-97
- Rosenthal L, Schisterman E. Pooling data when analyzing biomarkers subject to a limit of detection. Methods Mol Biol 2008;477:421-6
- Simpson KL, Whetton AD, Dive CJ. Quantitative mass spectrometry-based techniques for clinical use: Biomarker identification and quantification. J Chromatogr B Analyt Technol Biomed Life Sci 2008; doi:10.1016/j.jchromb.2008.11.023
- Lee JW, Hall M. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. J Chromatogr B Analyt Technol Biomed Life Sci 2008; doi:10.1016/j.jchromb.2008.11.022
- Taylor JM, Ankerst DP, Andridge RR. Validation of biomarker-based risk prediction models. Clin Cancer Res 2008;14:5977-83
- Lausted C, Hu Z, Hood L. Quantitative serum proteomics from surface plasmon resonance imaging. Mol Cell Proteomics 2008;7:2464-74
- Nolen B, Marrangoni A, Velikokhatnya L, A serum based analysis of ovarian epithelial tumorigenesis. Gynecol Oncol 2009;112:47-54
- Soyama A, Eguchi S, Takatsuki M, Significance of the serum level of soluble E-cadherin in patients with HCC. Hepatogastroenterology 2008;55:1390-3
- Lempiainen A, Stenman UH, Blomqvist C, Free beta-subunit of human chorionic gonadotropin in serum is a diagnostically sensitive marker of seminomatous testicular cancer. Clin Chem 2008;54:1840-3
- Mocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer 2008;123:2370-6
- Muller H, Haug U, Rothenbacher D, Evaluation of serum and urinary myeloid related protein-14 as a marker for early detection of prostate cancer. J Urol 2008;180:1309-12
- Jiang H, Guan G, Zhang R, Increased urinary excretion of orosomucoid is a risk predictor of diabetic nephropathy. Nephrology 2009; doi:10.1111/j.1440-1797.2008.01053.x
- Almaraz AC, Bobrow BJ, Wingerchuk DM, Serum neuron specific enolase to predict neurological outcome after cardiopulmonary resuscitation: a critically appraised topic. Neurologist 2009;15:44-8
- Su W, Jiao G, Yang C, Ye Y. Evaluation of apolipoprotein M as a biomarker of coronary artery disease. Clin Biochem 2009;42:365-70
- Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008;43:948-54
- Stahl-Zeng J, Langes V, Ossala R, High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol Cell Proteomics 2007;6:1809-1817
- Kitteringham NR, Jenkins RE, Lane CS, Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci 2008: published online November 14, 2008, doi:10.1016/j.jchromb.2008.11.013
- Keshishian H, Addona T, Burgess M, Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 2007;6:2212-29
- Anderson NL, Anderson NG, Pearson TW, A human proteome detection and quantitation project: hPDQ. Mol Cell Proteomics 2009; doi:10.1074/mcp.R800015-MCP200
- Beerenwinkel N, Antal T, Dingli D, Genetic progression and the waiting time to cancer. PLoS Comput Biol 2007;3:2239-46
- Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99
- Jass JR. Colorectal cancer: a multipathway disease. Crit Rev Oncog 2006;12:273-87
- Koike K. Molecular basis of hepatitis C virus-associated hepatocarcinogenesis: lessons from animal model studies. Clin Gastroenterol Hepatol 2005;3:S132-5
- Miller I, Eberini I, Gianazza E. Proteomics of lung physiopathology. Proteomics 2008;8:5053-73
- Griffith OL, Chiu CG, Gown AM, Biomarker panel diagnosis of thyroid cancer: a critical review. Expert Rev Anticancer Ther 2008;8:1399-413
- Parikh CR, Devarajan P. New biomarkers of acute kidney injury. Crit Care Med 2008;36:S159-65
- Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med 2007;11:1031-51
- Bailey P. Biological markers in Alzheimer's disease. Can J Neurol Sci 2007;34:S72-6
- Ye B, Gagnon A, Mok SC. Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Rev Proteomics 2007;4:121-31
- Meyer-Siegler KL, Bellino MA, Tannenbaum M. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 2002;94:1449-56
- Rosenzweig CN, Zhang Z, Sun X, Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J Urol 2009;181:1407-14
- Wenske S, Korets R, Cronin AM, Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy. Int J Cancer 2009;124:659-63
- Visintin I, Feng Z, Longton G, Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065-72
- Mor G, Visintin I, Lai Y, Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 2005;102:7677-82
- Xiao T, Ying W, Li L, An approach to studying lung cancer-related proteins in human blood. Mol Cell Proteomics 2005;4:1480-6
- Oikonomopoulou K, Li L, Zheng Y, Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer 2008;99:1103-13
- Gerszten RE, Accurso F, Bernard GR, Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. Am J Physiol Lung Cell Physiol 2008;295:L16-22
- Kirkpatrick DS, Gerber SA, Gygi SP. The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods 2005;35:265-73
- Blonder J, Veenstra TD. Computational prediction of proteotypic peptides. Expert Rev Proteomics 2007;4:351-4
- Sherman J, McKay MJ, Ashman K, Molloy MP. How specific is my SRM?: The issue of precursor and product ion redundancy. Proteomics 2009;9:1120-3
- Dooley KC. Tandem mass spectrometry in the clinical chemistry laboratory. Clin Biochem 2003;36:471-81
- Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmocokinet 2008;47:351-71
- Kirsch S, Widart J, Louette J, Development of an absolute quantification method targeting growth hormone biomarkers coupling liquid chromatography with isotope dilution mass spectrometry. J Chromatogr A 2007;1153:300-6
- Barnidge DR, Goodmanson MK, Klee GC, Muddiman DC. Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-MS/MS using protein cleavage and isotope dilution mass spectrometry. J Proteome Res 2004;3:644-52
- Patil ST, Higgs RE, Brandt JE, Identifying pharmacodynamic protein markers of centrally active drugs in humans: a pilot study in a novel clinical model. J Proteome Res 2007;6:955-66
- Wolf-Yadlin A, Hautaniemi S, Lauffenburger DA, Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc Natl Acad Sci USA 2007;104:5860-5
- Lange V, Malmstrom JA, Didion J, Targeted quantitative analysis of Streptococcus pyogenes virulence factors by multiple reaction monitoring. Mol Cell Proteomics 2008;7:1489-500
- Lamontagne J, Forest A, Marrazo E, Intracellular adaptation of Brucella abortus. J Proteome Res 2009;8:1594-609
- Bowers GN, Fassett JD, White ET, Isotope dilution mass spectrometry and the national reference system. Anal Chem 1993;65:475R-9R
- Barr JR, Maggio VL, Patterson DG, Isotope dilution-mass spectrometric quantification of specific proteins: model application with apolipoprotein A-1. Clin Chem 1996;42:1676-82
- Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5:573-88
- Bondar OP, Barnidge DR, Klee EW, LC-MS/MS quantification of Zn-alpha2 glycoprotein: a potential serum biomarker for prostate cancer. Clin Chem 2007;53:673-8
- Kay RG, Gregory B, Grace PB, Pleasance S. The application of ultra-performance liquid chromatography/tandem mass spectrometry to the detection and quantitation of apolipoproteins in human serum. Rapid Commun Mass Spectrom 2007;21:2585-93
- Williams DK, Muddiman DC. Absolute quantification of C-reactive protein in human plasma derived from patients with epithelial ovarian cancer utilizing protein cleavage isotope dilution mass spectrometry. J Proteome Res 2009;8:1085-90
- Kuhn E, Wu J, Karl J, Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labelled peptide standards. Proteomics 2004;4:1175-86
- Anderson NL, Anderson NG, Haines LR, Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J Proteome Res 2004;3:235-44
- Whiteaker JR, Zhao L, Zhang HY, Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal Biochem 2007;362:44-54
- Ackermann BL, Berna MJ. Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev Proteomics 2007;4:175-86
- Berna MJ, Zhen Y, Watson DE, Strategic use of immunoprecipitation and LC-MS/MS for trace-level protein quantification: myosin light chain 1, a biomarker of cardiac necrosis. Anal Chem 2007;79:4199-205
- Nicol GR, Han M, Kim J, Use of an immunoaffinity-mass spectrometry based approach for the quantitation of protein biomarkers from serum samples of lung cancer patients. Mol Cell Proteomics 2008;7:1974-82
- Kiernan UA, Nedelkov D, Nelson RW. Multiplexed mass spectrometric immunoassay in biomarker research: a novel approach to the determination of a myocardial infarct. J Proteome Res 2006;5:2928-34
- Kulasingam V, Smith CR, Batruch I, ‘Product ion monitoring’ assay for prostate-specific antigen in serum using a linear ion-trap. J Proteome Res 2008;7:640-7
- Martini L, Motta M, Piva F, Zanisi M. LHRF, LHRH, GnRH: what controls secretion of this hormone? Mol Psychiatry 1997;2:373-6
- Stanczyk FZ. Measurement of androgens in women. Semin Reprod Med 2006;24:78-85
- Shiraishi S, Lee PW, Leung A, Simultaneous measurement of serum testosterone and dihydrotestosterone by liquid chromatography-tandem mass spectrometry. Clin Chem 2008;54:1855-63
- Zweigenbaum J, Henion J. Bioanalytical high-throughput selected reaction monitoring-LC/MS determination of selected estrogen receptor modulators in human plasma: 2000 samples/day. Anal Chem 2000;72(11):2446-54
- Copeland S. A review of newborn screening in the era of tandem mass spectrometry: what's new for the pediatric neurologist? Semin Pediatr Neurol 2008;15:110-6
- Rinaldo P, Lim JS, Tortorelli S, Newborn screening of metabolic disorders: recent progress and future developments. Nestle Nutr Workshop Ser Pediatr Program 2008;62:81-93; discussion 93-6
- Mueller P, Schulze A, Schindler I, Validation of an ESI-MS/MS screening method for acylcarnitine profiling in urine specimens of neonates, children, adolescents and adults. Clin Chim Acta 2003;327:47-57
- Nedelkov D. Mass spectrometry-based immunoassays for the next phase of clinical applications. Exp Rev Proteomics 2006;3:631-40
- Nedelkov D, Kiernan UA, Niederkofler EE, Investigating diversity in human plasma proteins. Proc Natl Acad Sci USA 2005;102:10852-7
- Niederkofler EE, Kiernan UA, O'Rear J, Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail 2008;1:258-64
- Hoofnagle AN, Becker JO, Wener MH, Quantification of thyroglobulin, a low-abundance serum protein by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem 2008;54:1796-804
- ICH Harmonized Tripartite Guideline. Validation of analytical procedures: methodology, 6 November, 1996; Part I: page 1
- Viswanathan CT, Bansal S, Booth B, Workshop/Conference report – quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J 2007;9:E30-42
- FDA Guidance Document, 2005. Guidance for Industry. Pharmacogenomic Data Submissions. Available from: www.fda.gov/cder/guidance/6400fnl.pdf